Colorectal Cancer Clinical Trials & Research at St. Joseph Health Medical Group

Colorectal cancer is the third most common type of cancer in men and women in the U.S. Most colorectal cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Colorectal cancer often begins as a growth called a polyp, which may form on the inner wall of the colon or rectum. Some polyps become cancer over time. Finding and removing polyps can prevent colorectal cancer.

St. Joseph Health Medical Group is currently enrolling patients for the following colorectal cancer clinical trials:

Gastric Cancer
Colorectal Cancer


Gastric

A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy (BeiGene)

Phase III

The purpose of this study is to compare the efficacy and safety of single agent poly (ADP-ribose) polymerase (PARP) inhibitor BGB-290 to placebo as maintenance therapy in subjects with advanced or inoperable gastric cancer who have responded to first line platinum based chemotherapy. Subjects are randomized 1:1 to BGB-290 (Arm A) or placebo (Arm B). Patients must have achieved a partial response that is maintained for ≥ 4 weeks or a complete response with platinum-based first-line chemotherapy.

Treatment agent: BGB-290 (PARPi)
PI: Thomas Stanton, MD
Study Coordinator: Sabine Ucik // Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links: clinicaltrials.gov NCT No: NCT03427814


Colorectal

A Phase III Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem)

Phase III

This is an international multi-center, prospective, open-label trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in adult patients with metastatic colorectal cancer following progression on first-line FOLFOX or XELOX with or without bevacizumab.

Treatment agent: Napabucasin
PI: Ian Anderson, MD
Study Coordinator: Sabine Ucik // Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links: clinicaltrials.gov NCT No: NCT02753127

Our Locations